C4 Therapeutics presents Phase 1 biomarker gains for cemsidomide; 75 µg combo dose with elranatamab declared safe

C4 Therapeutics reported new biomarker data showing T—cell activation from the cemsidomide Phase 1 trial and supportive preliminary Phase 1b data with elranatamab; the 75 µg combination dose was declared safe and the Phase 1b is advancing to 100 µg escalation and 75 µg expansion.Key Highlights:Orig…